MedWatch

Wulff: Venture funds shy away from risks

Peter Wulff, Chairman in Skau Vaccines, believes that a lack of risk taking in regards to Danish investments in vaccines, can be explained by investors’ lack of understanding of the area.

Foto: Colourbox

In spite of a surge in happy stories about biotech companies able to attract powerful investors, not everyone is able to replenish their money pits. The young Aarhus-based biotech company Skau Vaccines, chaired by biotech heavyweight Peter Wulff, is one of the companies that have walked away from investor meetings empty handed .

“It has been very difficult for Skau to attract capital following the investment from Østjysk Innovation, and the company has been living off of funding from various projects. It looks like they will now get some money from a new EU program, so the company will soldier on. But it’s difficult to convince funds to invest in an early-stage project,” Peter Wulff tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier